tranScrip is delighted to announce that Dr Flic Gabbay has taken up office as the new President of the Faculty of Pharmaceutical Medicine (FPM). Flic, a co-founder of tranScrip, has spent 4 decades in drug development. Over the last 14 years, she has led tranScrip on multiple innovative projects and drug registrations for over 250 clients. Being elected President is particularly important to Flic as she Chaired the RCP London Steering Committee which founded FPM as part of the three UK Colleges of Physicians in 1989.Flic is an active Fellow of the Academy of Medical Science and is…
Cambridge and London, UK: 11 November 2021
One Nucleus, the not-for-profit Life Science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster, aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes. One Nucleus supports companies throughout their life cycle. This includes facilitating engagement between members and expert research partners and providers of key services and insight.
BioIVT, a leading provider of high-quality biological specimens and related services globally, recently…
Cambridge and Liverpool, UK, 9 November 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.
iiCON’s £174 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and products – saving and improving millions of…
London, UK, 8 November 2021 – Abingworth, a leading international life sciences investor, today announced the further strengthening of its investment team with the appointment of Jayson Punwani, PhD, MBA as Partner. Jayson will be based at the firm’s Menlo Park, CA office. He will work with the transatlantic team across all locations, actively seeking new opportunities and supporting existing investments in innovative private and public companies, at all stages of development, as well as those focused on clinical co-development. Jayson has more than 10 years’ experience in venture…
Leading pharmaceutical and biotech product development consultancy Boyds has further strengthened its clinical operations offering with the appointment of Pippa Bjaaland as a Senior Clinical Research Associate (CRA), as part of an ongoing recruitment drive to grow in-house CRA expertise.
Pippa brings more than five years’ industry experience in clinical operations and joins Boyds from Syneos Health where she was a Senior CRA working on Phase II-IV studies, primarily in oncology. Prior to this, she worked as an in-house CRA at PRA Health Sciences.
Pippa holds a BSc in Psychology from the…
Marie Curie, née Maria Sklodowska, was born in Warsaw on November 7, 1867. She died July 4th 1934.
I could read about this Polish-born French scientist, famous for her work on radioactivity and twice a winner of the Nobel Prize. for. hours! I have referenced her in several of my blog posts already. With Henri Becquerel and her husband, Pierre Curie, she was awarded the 1903 Nobel Prize for Physics. She was later the sole winner of the 1911 Nobel Prize for Chemistry.
She was the first woman to win a Nobel Prize, and she is the first person and only woman to win the award in two different…
A busy month ahead for the Virtual Innovation Centre with two workshops discussing important topics for those Life Science companies becoming more active deal makers:
Growing with Underlying Principles of Drug Development in Mind on 18 November 11.30–12.30 is for early stage companies who need to show their understanding of the underlying principles of drug
development to their stakeholders and ensure they know how to evolve them as the company grows.
In collaboration with
Anatomy of a Research Collaboration Agreement to provide a review of the…
LONDON and CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Blackstone Life Sciences today announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone (NYSE: BX) will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as…
Cambridge, UK, 8th November 2021: Chesterford Research Park is delighted to announce the expansion of existing occupier, CellCentric, within the Mansion House at the heart of the Park. The clinical stage biotechnology company focused on the development of a novel drug for specific cancers has renewed its current lease for Suite 3 in the 19th Century converted manor house, whilst at the same time expanding into Suite 4 within the same building.
Having secured $33m in funding from Morningside Venture Investments at the end of 2020, clinical trials for CellCentric’s novel drug CCS1477 have been…
CAMBRIDGE, UK, 5 November 2021 - today bit.bio announces the first close of their Series B financing of $103 million. New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.
The funding will accelerate the clinical development of the company’s proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently…